WO1994015607A1 - Application of lamotrigine in the treatment of parkinson's disease and parkinsonian syndromes - Google Patents

Application of lamotrigine in the treatment of parkinson's disease and parkinsonian syndromes Download PDF

Info

Publication number
WO1994015607A1
WO1994015607A1 PCT/FR1994/000005 FR9400005W WO9415607A1 WO 1994015607 A1 WO1994015607 A1 WO 1994015607A1 FR 9400005 W FR9400005 W FR 9400005W WO 9415607 A1 WO9415607 A1 WO 9415607A1
Authority
WO
WIPO (PCT)
Prior art keywords
lamotrigine
parkinson
disease
treatment
application
Prior art date
Application number
PCT/FR1994/000005
Other languages
French (fr)
Inventor
Alain Boireau
Adam Doble
Pierre Dubedat
Erik Louvel
Mireille Meunier
Jean-Marie Miquet
Jean-Marie Stutzmann
Françoise BORDIER
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Priority to AU58190/94A priority Critical patent/AU5819094A/en
Publication of WO1994015607A1 publication Critical patent/WO1994015607A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to a new therapeutic application of lamotrigine or the pharmaceutically acceptable salts of this compound.
  • Lamotrigine is described as anticonvulsant and antiepileptic in particular in patent EP 247892.
  • this compound can also be used in the treatment of Parkinson's disease and parkinsonian syndromes.
  • the activity of lamotrigine was therefore demonstrated in mice by measuring the decreases in the levels of striatal dopamine, 3,4-dihydroxy phenylacetic acid and homovanillic acid induced by MPTP compared with those of control animals.
  • mice 15 mg / kg of MPTP are injected 3 times at 2 hour intervals intraperitoneally into mice (C57BL / 6) weighing 20-25 g.
  • Thirty minutes before the first injection of MPTP then 2 hours and 30 minutes, 5 hours and 30 minutes and 7 hours and 30 minutes after the first injection of MPTP is administered according to the product from 1 to 40 mg / kg of the product to be studied.
  • twice a day depending on the product is administered from 1 to 40 mg / kg of the product to be studied.
  • the mice are sacrificed 8 days after the injection of MPTP.
  • the striatum is dissected and stored at -70 ° C until the time of its analysis.
  • Levels of dopamine, 3,4-dihydroxy acid Phenylacetic and homovanillic acid are measured by high pressure liquid chromatography with electrochemical detection. Statistical analyzes are performed using ANOVA followed by the SCHEFFE test.
  • lamotrigine is capable of preventing decreases in the levels of dopamine, 3,4-dihydroxy phenylacetic acid and homovanillic acid induced by MPTP in the stiatum.
  • salts with mineral acids such as hydrochloride, sulfate, nitrate, phosphate or organic salts such as acetate, propionate, succinate, oxalate, benzoate, fumarate, maleate, methanesulfonate, isethionate, theophillin- acetate, salicylate, phenoiphtalinate, methylene-bis- ⁇ -oxynaphtoate or substitution derivatives of these derivatives.
  • mineral acids such as hydrochloride, sulfate, nitrate, phosphate or organic salts such as acetate, propionate, succinate, oxalate, benzoate, fumarate, maleate, methanesulfonate, isethionate, theophillin- acetate, salicylate, phenoiphtalinate, methylene-bis- ⁇ -oxynaphtoate or substitution derivatives of these derivatives.
  • the medicinal products consist at least of lamotrigine in free form or in salt form • of acid addition pharmaceutically acceptable, in the pure state or in the form of a composition in which it is associated with any other pharmaceutically compatible product, which may be inert or physiologically active.
  • the medicaments according to the invention can be used orally or parenterally.
  • compositions for oral administration tablets, pills, powders (gelatin capsules, cachets) or granules can be used.
  • the active principle according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon.
  • inert diluents such as starch, cellulose, sucrose, lactose or silica
  • These compositions can also comprise substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a dye, a coating (dragees) or a varnish.
  • liquid compositions for oral administration • pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or the like may be used. paraffin oil.
  • inert diluents such as water, ethanol, glycerol, vegetable oils or the like
  • paraffin oil can be used.
  • These compositions can include substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
  • the sterile compositions for parenteral administration can preferably be aqueous or non-aqueous solutions, suspensions or emulsions.
  • solvent or vehicle water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or other organic solvents can be used. suitable.
  • These compositions can also contain adjuvants, in particular wetting agents, isotonizers, emulsifiers, dispersants and stabilizers. Sterilization can be done in several ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating.
  • sterile solid compositions which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
  • the doses depend on the desired effect, on the duration of the treatment and on the route of administration used; they are generally between 50 and 400 mg per day orally for an adult with unit doses ranging from 25 to 200 mg of active substance.
  • the doctor will determine the appropriate dosage based on age, weight and all other factors specific to the subject to be treated.
  • capsules containing 50 mg of active product having the following composition are prepared:
  • a solution for injection containing 10 mg of active product having the following composition is prepared:
  • the invention also relates to the process for the preparation of medicaments useful in the treatment of Parkinson's disease and of parkinsonian syndromes comprising mixing lamotrigine or the pharmaceutically acceptable salts of this compound with one or more compatible and pharmaceutically acceptable diluents and / or adjuvants .
  • the invention also relates to a method of treating a mammal and, in particular a man, presenting with Parkinson's disease or parkinsonian syndromes comprising the administration of an effective amount of lamotrigine or pharmaceutically acceptable salts of this compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Application of lamotrigine or its pharmaceutically acceptable salts in the preparation of drugs for the treatment of Parkinson's disease and parkinsonian syndromes.

Description

APPLICATION DE LA LAMOTRIGINE APPLICATION OF LAMOTRIGINE
DANS LE TRAITEMENT DE LA MALADIE DE PARKINSONIN THE TREATMENT OF PARKINSON'S DISEASE
ET DES SYNDROMES PARKINSONIENSAND PARKINSONIAN SYNDROMES
La présente invention concerne une nouvelle application thérapeutique de la lamotrigine ou les sels pharmaceutiquement acceptables de ce composé.The present invention relates to a new therapeutic application of lamotrigine or the pharmaceutically acceptable salts of this compound.
La lamotrigine est décrite comme anticonvulsivant et antiépileptique notamment dans le brevet EP 247892.Lamotrigine is described as anticonvulsant and antiepileptic in particular in patent EP 247892.
Il a maintenant été trouvé de manière surprenante que ce composé peut aussi être utilisé dans le traitement de la maladie de Parkinson et des syndromes parkinson iens.It has now surprisingly been found that this compound can also be used in the treatment of Parkinson's disease and parkinsonian syndromes.
Il est connu que la neurotoxine MPTP (1-méthyl-4-phényl-1 ,2,3,6- tétrahydropyridine) induit un syndrome similaire à la maladie de Parkinson. Ce syndrome résulte d'une dégénération des neurones nigrostriataux dopaminergiques chez les primates (R. S. BURNS et coll., Proc. Natl. Acad. Sci., 80, 4546-4550 (1983), chez l'homme (J. W. LANGSTON et coll., Science, 219, 979-980 (1983)) et chez la souris (R. E. HEIKKILA et coll., Science, 224, 1451-1453 (1984).It is known that the neurotoxin MPTP (1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine) induces a syndrome similar to Parkinson's disease. This syndrome results from a degeneration of dopaminergic nigrostriatal neurons in primates (RS BURNS et al., Proc. Natl. Acad. Sci., 80, 4546-4550 (1983), in humans (JW LANGSTON et al., Science, 219, 979-980 (1983)) and in mice (RE HEIKKILA et al., Science, 224, 1451-1453 (1984).
L'activité de la lamotrigine a donc été mise en évidence chez la souris en mesurant les diminutions des taux de dopamine striatale, d'acide dihydroxy-3,4 phénylacétique et d'acide homovanillique induites par la MPTP comparées à celles des animaux témoins.The activity of lamotrigine was therefore demonstrated in mice by measuring the decreases in the levels of striatal dopamine, 3,4-dihydroxy phenylacetic acid and homovanillic acid induced by MPTP compared with those of control animals.
On injecte, 3 fois à 2 heures d'intervalle, 15 mg/kg de MPTP par voie intrapéritonéale à des souris (C57BL/6) pesant 20-25 g. Trente minutes avant la première injection de MPTP, puis 2 heures et 30 minutes, 5 heures et 30 minutes et 7 heures et 30 minutes après la première injection de MPTP on administre selon le produit de 1 à 40 mg/kg du produit à étudier. Durant les 3 jours suivants, on administre 2 fois par jour selon le produit de 1 à 40 mg/kg du produit à étudier. Les souris sont sacrifiées 8 jours après l'injection de MPTP. Le striatum est disséqué et conservé à -70°C jusqu'au moment de son analyse. Les taux de dopamine, d'acide dihydroxy-3,4 phénylacétique et d'acide homovanillique sont mesurés par chromatographie liquide haute pression avec une détection électrochimique. Les analyses statistiques sont effectuées en utilisant ANOVA suivi par le test de SCHEFFE.15 mg / kg of MPTP are injected 3 times at 2 hour intervals intraperitoneally into mice (C57BL / 6) weighing 20-25 g. Thirty minutes before the first injection of MPTP, then 2 hours and 30 minutes, 5 hours and 30 minutes and 7 hours and 30 minutes after the first injection of MPTP is administered according to the product from 1 to 40 mg / kg of the product to be studied. During the following 3 days, twice a day depending on the product is administered from 1 to 40 mg / kg of the product to be studied. The mice are sacrificed 8 days after the injection of MPTP. The striatum is dissected and stored at -70 ° C until the time of its analysis. Levels of dopamine, 3,4-dihydroxy acid Phenylacetic and homovanillic acid are measured by high pressure liquid chromatography with electrochemical detection. Statistical analyzes are performed using ANOVA followed by the SCHEFFE test.
Les résultats obtenus sont mentionnés dans le tableau suivant :The results obtained are mentioned in the following table:
Figure imgf000004_0001
Figure imgf000004_0001
Ces résultats démontrent bien que la lamotrigine est capable de prévenir les diminutions des taux de dopamine, d'acide dihydroxy-3,4 phénylacétique et d'acide homovanillique induites par la MPTP dans le stiatum.These results clearly demonstrate that lamotrigine is capable of preventing decreases in the levels of dopamine, 3,4-dihydroxy phenylacetic acid and homovanillic acid induced by MPTP in the stiatum.
Comme sels pharmaceutiquement acceptables peuvent être notamment cités les sels d'addition avec les acides minéraux tels que chlorhydrate, sulfate, nitrate, phosphate ou organiques tels que acétate, propionate, succinate, oxalate, benzoate, fumarate, maléate, méthanesulfonate, iséthionate, théophilline-acétate, salicylate, phénoiphtalinate, méthylène-bis-β-oxynaphtoate ou des dérivés de substitution de ces dérivés.As pharmaceutically acceptable salts, mention may in particular be made of addition salts with mineral acids such as hydrochloride, sulfate, nitrate, phosphate or organic salts such as acetate, propionate, succinate, oxalate, benzoate, fumarate, maleate, methanesulfonate, isethionate, theophillin- acetate, salicylate, phenoiphtalinate, methylene-bis-β-oxynaphtoate or substitution derivatives of these derivatives.
Les médicaments sont constitués par au moins la lamotrigine sous forme libre ou sous forme d'un sel • d'addition avec un acide pharmaceutiquement acceptable, à l'état pur ou sous forme d'une composition dans laquelle il est associé à tout autre produit pharmaceutiquement compatible, pouvant être inerte ou physiologiquement actif. Les médicaments selon l'invention peuvent être employés par voie orale ou parentérale.The medicinal products consist at least of lamotrigine in free form or in salt form • of acid addition pharmaceutically acceptable, in the pure state or in the form of a composition in which it is associated with any other pharmaceutically compatible product, which may be inert or physiologically active. The medicaments according to the invention can be used orally or parenterally.
Comme compositions solides pour administration orale, peuvent être utilisés des comprimés, des pilules, des poudres (capsules de gélatine, cachets) ou des granulés. Dans ces compositions, le principe actif selon l'invention est mélangé à un ou plusieurs diluants inertes, tels que amidon, cellulose, saccharose, lactose ou silice, sous courant d'argon. Ces compositions peuvent également comprendre des substances autres que les diluants, par exemple un ou plusieurs lubrifiants tels que le stéarate de magnésium ou le talc, un colorant, un enrobage (dragées) ou un vernis.As solid compositions for oral administration, tablets, pills, powders (gelatin capsules, cachets) or granules can be used. In these compositions, the active principle according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon. These compositions can also comprise substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a dye, a coating (dragees) or a varnish.
Comme compositions liquides pour administration orale, • on peut utiliser des solutions, des suspensions, des émuisions, des sirops et des élixirs pharmaceutiquement acceptables contenant des diluants inertes tels que l'eau, l'éthanol, le glycérol, les huiles végétales ou l'huile de paraffine. Ces compositions peuvent comprendre des substances autres que les diluants, par exemple des produits mouillants, édulcorants, épaississants, aromatisants ou stabilisants.As liquid compositions for oral administration, • pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or the like may be used. paraffin oil. These compositions can include substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
Les compositions stériles pour administration parentérale, peuvent être de préférence des solutions aqueuses ou non aqueuses, des suspensions ou des émuisions. Comme solvant ou véhicule, on peut employer l'eau, le propylènegiycol, un polyéthylèneglycol, des huiles végétales, en particulier l'huile d'olive, des esters organiques injectables, par exemple l'oléate d'éthyle ou d'autres solvants organiques convenables. Ces compositions peuvent également contenir des adjuvants, en particulier des agents mouillants, isotonisants, émulsifiants, dispersants et stabilisants. La stérilisation peut se faire de plusieurs façons, par exemple par filtration aseptisante, en incorporant à la composition des agents stérilisants, par irra¬ diation ou par chauffage. Elles peuvent également être préparées sous forme de compositions solides stériles qui peuvent être dissoutes au moment de l'emploi dans de l'eau stérile ou tout autre milieu stérile injectable. Les doses dépendent de l'effet recherché, de la durée du traitement et de la voie d'administration utilisée ; elles sont généralement comprises entre 50 et 400 mg par jour par voie orale pour un adulte avec des doses unitaires allant de 25 à 200 mg de substance active.The sterile compositions for parenteral administration can preferably be aqueous or non-aqueous solutions, suspensions or emulsions. As solvent or vehicle, water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or other organic solvents can be used. suitable. These compositions can also contain adjuvants, in particular wetting agents, isotonizers, emulsifiers, dispersants and stabilizers. Sterilization can be done in several ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water or any other sterile injectable medium. The doses depend on the desired effect, on the duration of the treatment and on the route of administration used; they are generally between 50 and 400 mg per day orally for an adult with unit doses ranging from 25 to 200 mg of active substance.
D'une façon générale, le médecin déterminera la posologie appropriée en fonction de l'âge, du poids et de tous les autres facteurs propres au sujet à traiter.In general, the doctor will determine the appropriate dosage based on age, weight and all other factors specific to the subject to be treated.
Les exemples suivants illustrent des médicaments selon l'invention :The following examples illustrate medicaments according to the invention:
Exemple AExample A
On prépare, selon la technique habituelle, des comprimés dosés àUsing the usual technique, tablets dosed at
50 mg de produit actif ayant la composition suivante :50 mg of active product having the following composition:
- Produit actif 50 mg- Active product 50 mg
- Mannitol 64 mg- Mannitol 64 mg
- Cellulose microcristalline 50 mg - Polyvidone excipient 12 mg- Microcrystalline cellulose 50 mg - Polyvidone excipient 12 mg
- Carboxyméthylamidon sodique 16 mg- Carboxymethyl starch sodium 16 mg
- Talc 4 mg- Talc 4 mg
- Stéarate de magnésium 2 mg- Magnesium stearate 2 mg
- Silice colloïdale anhydre 2 mg - Mélange de méthylhydroxypropylcellulose, polyéthylèneglycol 6000, dioxyde de titane (72-3,5-24,5) q.s.p. 1 comprimé pellicule terminé à 245 mg- Anhydrous colloidal silica 2 mg - Mixture of methylhydroxypropylcellulose, polyethylene glycol 6000, titanium dioxide (72-3,5-24,5) q.s.p. 1 film-coated tablet finished at 245 mg
Exemple BExample B
On prépare, selon la technique habituelle, des gélules dosées à 50 mg de produit actif ayant la composition suivante :Using the usual technique, capsules containing 50 mg of active product having the following composition are prepared:
- Produit actif 50 mg- Active product 50 mg
- Cellulose 18 mg- Cellulose 18 mg
- Lactose 55 mg- Lactose 55 mg
- Silice colloïdale 1 mg - Carboxyméthylamidon sodique 10 mg - Talc 10 mg- Colloidal silica 1 mg - Carboxymethyl starch sodium 10 mg - Talc 10 mg
- Stéarate de magnésium 1 mg- Magnesium stearate 1 mg
Exemple CExample C
On prépare une solution injectable contenant 10 mg de produit actif ayant la composition suivante :A solution for injection containing 10 mg of active product having the following composition is prepared:
- Produit actif 10 mg- Active product 10 mg
- Acide benzoïque 80 mg- Benzoic acid 80 mg
- Alcool benzylique 0,06 cm3- Benzyl alcohol 0.06 cm3
- Benzoate de sodium 80 mg - Ethanol à 95 % 0,4 cm3- Sodium benzoate 80 mg - 95% ethanol 0.4 cm3
- Hydroxyde de sodium 24 mg- Sodium hydroxide 24 mg
- Propylène glycol 1 ,6 cm3- Propylene glycol 1.6 cm3
L'invention concerne également le procédé de préparation de médicaments utiles dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens consistant à mélanger la lamotrigine ou les sels pharmaceutiquement acceptables de ce composé avec un ou plusieurs diluants et/ou adjuvants compatibles et pharmaceutiquement acceptables.The invention also relates to the process for the preparation of medicaments useful in the treatment of Parkinson's disease and of parkinsonian syndromes comprising mixing lamotrigine or the pharmaceutically acceptable salts of this compound with one or more compatible and pharmaceutically acceptable diluents and / or adjuvants .
L'invention concerne également une méthode de traitement d'un mammifère et, notamment l'homme, présentant la maladie de Parkinson ou des syndromes parkinsoniens comprenant l'administration d'une quantité efficace de lamotrigine ou des sels pharmaceutiquement acceptables de ce composé. The invention also relates to a method of treating a mammal and, in particular a man, presenting with Parkinson's disease or parkinsonian syndromes comprising the administration of an effective amount of lamotrigine or pharmaceutically acceptable salts of this compound.

Claims

REVENDICATIONS
1 - Application de la lamotrigine ou les sels pharmaceutiquement acceptables de ce composé à la préparation de médicaments destinés au traitement de la maladie de Parkinson et des syndromes parkinsoniens.1 - Application of lamotrigine or the pharmaceutically acceptable salts of this compound to the preparation of medicaments intended for the treatment of Parkinson's disease and parkinsonian syndromes.
2 - Application selon la revendication 1 pour obtenir un médicament comprenant 25 à 200 mg de lamotrigine.2 - Application according to claim 1 to obtain a medicament comprising 25 to 200 mg of lamotrigine.
3 - Procédé de préparation d'un médicament utile pour le traitement de la maladie de Parkinson et des syndromes parkinsoniens caractérisé en ce que l'on mélange la lamotrigine ou les sels pharmaceutiquement acceptables de ce composé avec un ou plusieurs diluants et/ou adjuvants compatibles et pharmaceutiquement acceptables. 3 - Process for the preparation of a medicament useful for the treatment of Parkinson's disease and parkinsonian syndromes characterized in that the lamotrigine or the pharmaceutically acceptable salts of this compound are mixed with one or more compatible diluents and / or adjuvants and pharmaceutically acceptable.
PCT/FR1994/000005 1993-01-07 1994-01-03 Application of lamotrigine in the treatment of parkinson's disease and parkinsonian syndromes WO1994015607A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58190/94A AU5819094A (en) 1993-01-07 1994-01-03 Application of lamotrigine in the treatment of parkinson's disease and parkinsonian syndromes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR93/00074 1993-01-07
FR9300074A FR2700117B1 (en) 1993-01-07 1993-01-07 Application of anti-convulsants in the treatment of Parkinson's disease and parkinsonian syndromes.

Publications (1)

Publication Number Publication Date
WO1994015607A1 true WO1994015607A1 (en) 1994-07-21

Family

ID=9442862

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/FR1994/000003 WO1994015601A1 (en) 1993-01-07 1994-01-03 Application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes
PCT/FR1994/000005 WO1994015607A1 (en) 1993-01-07 1994-01-03 Application of lamotrigine in the treatment of parkinson's disease and parkinsonian syndromes
PCT/FR1994/000004 WO1994015610A1 (en) 1993-01-07 1994-01-03 Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/FR1994/000003 WO1994015601A1 (en) 1993-01-07 1994-01-03 Application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/FR1994/000004 WO1994015610A1 (en) 1993-01-07 1994-01-03 Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes

Country Status (23)

Country Link
US (2) US5658900A (en)
EP (2) EP0678023B1 (en)
JP (2) JP3120153B2 (en)
KR (2) KR100298807B1 (en)
AT (2) ATE144420T1 (en)
AU (3) AU684059B2 (en)
CA (2) CA2153341A1 (en)
CZ (2) CZ284363B6 (en)
DE (2) DE69400799T2 (en)
DK (2) DK0678026T3 (en)
ES (2) ES2092890T3 (en)
FR (1) FR2700117B1 (en)
GR (2) GR3020975T3 (en)
HU (2) HUT72074A (en)
IL (3) IL108286A0 (en)
MX (2) MX9307885A (en)
NO (2) NO952310D0 (en)
PL (2) PL309594A1 (en)
RU (1) RU2221563C2 (en)
SK (2) SK279645B6 (en)
UA (1) UA29464C2 (en)
WO (3) WO1994015601A1 (en)
ZA (3) ZA9426B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6119094A (en) * 1996-02-29 2000-09-12 Electronic Data Systems Corporation Automated system for identifying alternate low-cost travel arrangements
PL342098A1 (en) * 1998-01-09 2001-05-21 Mor Research Applic Ltd Pharmacological compositions for treating diskineses
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
FR2774592B1 (en) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa APPLICATION OF 2-AMINO-6-TRIFLUOROMETHOXYBENZOTHIAZOLE FOR THE PREVENTION OR TREATMENT OF BRAIN MALFUNCTIONS
FR2777781B1 (en) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa RILUZOLE AND L-DOPA ASSOCIATIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
FR2787028B1 (en) 1998-12-15 2002-10-18 Aventis Pharma Sa USE OF RILUZOLE IN THE TREATMENT OF ACOUSTIC TRAUMA
US6506378B1 (en) * 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
FR2801793B1 (en) * 1999-12-01 2003-07-04 Aventis Pharma Sa COMBINATION OF ERGOLIN AND RILUZOLE AND ITS USE AS A MEDICINAL PRODUCT
US7183272B2 (en) * 2001-02-12 2007-02-27 Teva Pharmaceutical Industries Ltd. Crystal forms of oxcarbazepine and processes for their preparation
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
WO2005037276A1 (en) * 2003-10-09 2005-04-28 Aventis Pharma S.A. Use of riluzole for the treatment of essential tremor
CA2471666C (en) * 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
WO2007022568A1 (en) 2005-08-25 2007-03-01 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
WO2007089247A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
US20070248684A1 (en) * 2006-01-31 2007-10-25 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
AU2007242984B2 (en) * 2006-04-26 2012-11-08 Supernus Pharmaceuticals Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
NZ583851A (en) * 2007-09-14 2012-06-29 Formycon Gmbh Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
MX353752B (en) 2009-01-20 2018-01-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical.
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US8809617B2 (en) 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
US11008277B2 (en) 2016-06-13 2021-05-18 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
US10815184B2 (en) 2016-06-13 2020-10-27 Syneurx International (Taiwan) Corp. Co-crystals of lithium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
EP4031135A4 (en) * 2019-09-20 2023-10-18 Icahn School of Medicine at Mount Sinai Controlled release formulations of riluzole and their uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247892A1 (en) * 1986-05-30 1987-12-02 The Wellcome Foundation Limited Triazine salt
EP0517347A1 (en) * 1991-06-05 1992-12-09 Schering Aktiengesellschaft New combinations for the treatment of Parkinsons disease, containing NMDA-antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
CH500196A (en) * 1969-03-10 1970-12-15 Ciba Geigy Ag Process for the production of new azepine derivatives
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
FR2492258A1 (en) * 1980-10-17 1982-04-23 Pharmindustrie NEW AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE-BASED MEDICINAL PRODUCT
FR2699077B1 (en) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application of anticonvulsants in the treatment of neurological lesions linked to trauma.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247892A1 (en) * 1986-05-30 1987-12-02 The Wellcome Foundation Limited Triazine salt
EP0517347A1 (en) * 1991-06-05 1992-12-09 Schering Aktiengesellschaft New combinations for the treatment of Parkinsons disease, containing NMDA-antagonists

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A.A. SHANDRA ET AL.: "EFFECTS OF LAMOTRIGINE ON KAINATE-INDUCED EPILEPTIC ACTIVITY AND PARKINSONISM", EPILEPSIA, vol. 32, no. S1, 1991, pages 60 - 61 *
E.G. MCGEER ET AL.: "LAMOTRIGINE PROTECTS AGAINST KAINATE BUT NOT IBOTENATE LESIONS IN RAT STRIATUM", NEUROSCIENCE LETTERS, vol. 112, no. 2-3, 1990, pages 348 - 351 *
F. ZIPP ET AL.: "LAMOTRIGINE-ANTIPARKINSONIAN ACTIVITY BY BLOCKAGE OF GLUTAMATE RELEASE?", JOURNAL OF NEURAL TRANSMISSION, vol. 5, no. 1, 8 January 1993 (1993-01-08), pages 67 - 75 *
J.K.C. TSUI: "FUTURE TREATMENT OF PARKINSON'S DISEASE", THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, vol. 19, no. 1, 1992, pages 160 - 162 *
M.J. LEACH ET AL.: "NEUROCHEMICAL AND BEHAVIORAL ASPECTS OF LAMOTRIGINE", EPILEPSIA, vol. 32, no. SUPL, 1991, pages S4 - S8 *
M.J. LEACH ET AL.: "PHARMACOLOGICAL STUDIES ON LAMOTRIGINE, A NOVEL POTENTIAL ANTIEPILEPTIC DRUG: II. NEUROCHEMICAL STUDIES ON THE MECHANISM OF ACTION", EPILEPSIA, vol. 27, no. 5, 1986, pages 490 - 497 *
T. KLOCKGETHER: "EXCITATORY AMINO ACIDS AND THE BASAL GANGLIA: IMPLICATIONS FOR THE THERAPY OF PARKINSON'S DISEASE", TRENDS IN NEUROSCIENCES, vol. 12, no. 8, 1989, pages 285 - 286 *

Also Published As

Publication number Publication date
PL309594A1 (en) 1995-10-30
PL309596A1 (en) 1995-10-30
NO952309L (en) 1995-06-12
DE69400799T2 (en) 1997-03-13
ZA9426B (en) 1994-08-11
CA2153340A1 (en) 1994-07-21
ES2091689T3 (en) 1996-11-01
AU5819094A (en) 1994-08-15
DK0678026T3 (en) 1996-09-16
CA2153341A1 (en) 1994-07-21
IL108284A (en) 1999-03-12
ZA9432B (en) 1994-08-11
MX9400287A (en) 1994-07-29
NO307495B1 (en) 2000-04-17
ATE141792T1 (en) 1996-09-15
ES2092890T3 (en) 1996-12-01
CA2153340C (en) 2002-12-17
DK0678023T3 (en) 1996-11-25
EP0678023B1 (en) 1996-10-23
CZ284363B6 (en) 1998-11-11
CZ176595A3 (en) 1995-12-13
UA29464C2 (en) 2000-11-15
SK279645B6 (en) 1999-01-11
NO952310L (en) 1995-06-12
JPH08505379A (en) 1996-06-11
NO952309D0 (en) 1995-06-12
HU9502065D0 (en) 1995-09-28
CZ284928B6 (en) 1999-04-14
WO1994015610A1 (en) 1994-07-21
EP0678026B1 (en) 1996-08-28
KR960700054A (en) 1996-01-19
KR100298807B1 (en) 2001-11-22
EP0678023A1 (en) 1995-10-25
AU684059B2 (en) 1997-12-04
IL108286A0 (en) 1994-04-12
US5658900A (en) 1997-08-19
KR960700059A (en) 1996-01-19
RU2221563C2 (en) 2004-01-20
SK86695A3 (en) 1996-05-08
AU5818994A (en) 1994-08-15
AU677279B2 (en) 1997-04-17
ZA9428B (en) 1994-08-11
FR2700117B1 (en) 1995-02-03
JPH08505378A (en) 1996-06-11
DE69400435T2 (en) 1997-03-06
EP0678026A1 (en) 1995-10-25
FR2700117A1 (en) 1994-07-08
WO1994015601A1 (en) 1994-07-21
GR3020975T3 (en) 1996-12-31
SK279758B6 (en) 1999-03-12
DE69400799D1 (en) 1996-11-28
GR3021438T3 (en) 1997-01-31
US5674885A (en) 1997-10-07
HU9502063D0 (en) 1995-09-28
HUT72328A (en) 1996-04-29
MX9307885A (en) 1994-07-29
AU5818894A (en) 1994-08-15
HUT72074A (en) 1996-03-28
ATE144420T1 (en) 1996-11-15
IL108285A0 (en) 1994-04-12
SK86795A3 (en) 1995-11-08
NO952310D0 (en) 1995-06-12
IL108284A0 (en) 1994-04-12
DE69400435D1 (en) 1996-10-02
CZ176495A3 (en) 1995-12-13
JP3120153B2 (en) 2000-12-25
HU217136B (en) 1999-11-29

Similar Documents

Publication Publication Date Title
EP0678026B1 (en) Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes
EP0627919B1 (en) Application of 2-amino 6-trifluoromethoxy benzothiazole (riluzole) for obtaining a drug useful in the treatment of motor neuron diseases
EP0687176B1 (en) Use of riluzole for treating aids-related neural disorders
EP0738147A1 (en) Application of riluzole in the treatment of mitochondrial diseases
EP0305276A2 (en) Use of 2-amino-6-trifluoromethoxybenzothiazole for the preparation of a medicament for the treatment of schizophrenia
EP0305277A2 (en) Use of 2-amino-6-trifluoromethoxybenzothiazole for the preparation of a medicament for the treatment of sleep disorders and depression
EP1212119A1 (en) Use of cyamemazine for cold turkey benzodiazepine treatment
EP0939636A1 (en) Application of thalidomide to the treatment of parkinson's disease and parkisonian syndromes
FR2700114A1 (en) Use of the anticonvulsant lamotrigin and its salts
FR2702149A1 (en) Application of lamotrigine in the treatment of neuro-AIDS
FR2700115A1 (en) Use of anticonvulsants carbamazepine and oxcarbazepine
EP0866703A1 (en) Use of 2-aminobenzothiazoles for treating parkinson's disease and parkinsonian syndromes
FR2702151A1 (en) Application of anticonvulsants in the treatment of neuro-AIDS
EP0374042A2 (en) Use of carbipramine in the preparation of a medicament for the treatment of anxiety and sleeping disorders
FR2741804A1 (en) APPLICATION OF 2-IMINOBENZOTHIAZOLINES IN THE TREATMENT OF PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES
FR2700116A1 (en) Application of anticonvulsants as radioprotectants.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CZ HU JP KR NO PL RU SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA